Ionis Pharmaceuticals Inc- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Ionis Pharmaceuticals Inc 公司

Ionis Pharmaceuticals, Inc. 從事核糖核酸 (RNA) 靶向治療。該公司有五種已上市藥物和一條產品線，涉及神經病學、心臟病學和其他患者需求高的領域。該公司有九種藥物處於 III 期開發階段，還有多種其他藥物處於早期和中期開發階段。該公司的產品包括 SPINRAZA、QALSODY、WAINUA、TEGSEDI 和 WAYLIVRA。SPINRAZA 用於治療脊髓性肌萎縮症 (SMA) 患者，這是一種進行性、使人衰弱且通常致命的遺傳疾病。QALSODY 是一種反義藥物，用於治療超氧化物歧化酶 1 肌萎縮側索硬化症 (SOD1-ALS) 的成年患者，這是一種罕見的神經退行性疾病，會導致運動神經元逐漸喪失並導致死亡。 WAINUA 是一種自行注射的皮下配體結合反義 (LICA) 藥物，用於治療患有遺傳性轉甲狀腺素介導的澱粉樣變性多發性神經病 (ATTRv-PN) 的成年人。

Ionis Pharmaceuticals Inc簡介



公司代碼IONS

公司名稱Ionis Pharmaceuticals Inc

上市日期May 17, 1991

CEODr. Brett P. Monia, Ph.D.

員工數量1069

證券類型Ordinary Share

年結日May 17

公司地址2855 Gazelle Court

城市CARLSBAD

上市交易所NASDAQ Global Select Consolidated

國家United States of America

郵編92010

電話17609319200

網址https://www.ionis.com/

公司代碼IONS

上市日期May 17, 1991

CEODr. Brett P. Monia, Ph.D.

Ionis Pharmaceuticals Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Brett P. Monia, Ph.D.

Chief Executive Officer, Director

180.01K

--

Dr. Spencer R. Berthelsen, M.D.

Independent Director

156.08K

+2.68%

Ms. Elizabeth L. Hougen

Chief Financial Officer, Executive Vice President - Finance

110.50K

--

Dr. Richard S. Geary, Ph.D.

Executive Vice President, Chief Development Officer

79.66K

-11.15%

Mr. Patrick R. O'Neil, Esq.

Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary

57.13K

--

Mr. Brian Birchler

Executive Vice President, Chief Business Officer

56.83K

+0.29%

Mr. Eugene Schneider, M.D.

Executive Vice President, Chief Clinical Development and Operations Officer

47.47K

--

Dr. Eric E. Swayze, Ph.D.

Executive Vice President - Research

37.42K

--

Dr. Joseph Loscalzo, M.D., Ph.D.

Independent Chairman of the Board

36.33K

--

Ms. Shannon L. Devers

Chief Human Resources Officer, Executive Vice President

15.94K

--

名稱

名稱/職務

職務

持股

持股變動

Dr. Brett P. Monia, Ph.D.

Chief Executive Officer, Director

180.01K

--

Dr. Spencer R. Berthelsen, M.D.

Independent Director

156.08K

+2.68%

Ms. Elizabeth L. Hougen

Chief Financial Officer, Executive Vice President - Finance

110.50K

--

Dr. Richard S. Geary, Ph.D.

Executive Vice President, Chief Development Officer

79.66K

-11.15%

Mr. Patrick R. O'Neil, Esq.

Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary

57.13K

--

Mr. Brian Birchler

Executive Vice President, Chief Business Officer

56.83K

+0.29%

收入明細

單位: USD更新時間: 3月4日週二

FY2020

FY2019

業務USD

名稱

營收

佔比

R&D revenue under collaborative agreements

364.56M

49.99%

SPINRAZA royalties

286.58M

39.30%

Product sales, net

70.00M

9.60%

Licensing and other Royalty revenue

8.12M

1.11%

暫無數據

業務

地區

業務USD

名稱

營收

佔比

R&D revenue under collaborative agreements

364.56M

49.99%

SPINRAZA royalties

286.58M

39.30%

Product sales, net

70.00M

9.60%

Licensing and other Royalty revenue

8.12M

1.11%

股東統計

更新時間: 8月23日週六

持股股東

股東類型

持股股東

佔比

Fidelity Management & Research Company LLC

14.83%

The Vanguard Group, Inc.

10.47%

T. Rowe Price Investment Management, Inc.

10.07%

Capital World Investors

7.87%

BlackRock Institutional Trust Company, N.A.

5.47%

其他

51.29%

持股股東

佔比

Fidelity Management & Research Company LLC

14.83%

The Vanguard Group, Inc.

10.47%

T. Rowe Price Investment Management, Inc.

10.07%

Capital World Investors

7.87%

BlackRock Institutional Trust Company, N.A.

5.47%

其他

51.29%

股東類型

持股股東

佔比

Investment Advisor

70.88%

Investment Advisor/Hedge Fund

17.08%

Hedge Fund

16.01%

Research Firm

2.02%

Pension Fund

1.13%

Individual Investor

0.78%

Bank and Trust

0.68%

Sovereign Wealth Fund

0.28%

Family Office

0.02%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

790

172.50M

108.22%

-7.29M

2025Q2

801

185.40M

116.34%

+8.33M

2025Q1

826

174.18M

109.45%

-1.97M

2024Q4

819

166.51M

104.84%

-2.69M

2024Q3

814

162.85M

103.55%

+6.60M

2024Q2

810

149.96M

102.64%

-3.87M

2024Q1

792

148.14M

101.63%

-5.27M

2023Q4

782

147.15M

102.53%

-3.26M

2023Q3

763

145.13M

101.24%

-1.40M

2023Q2

770

142.08M

99.29%

+364.04K

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Fidelity Management & Research Company LLC

23.64M

14.83%

+29.41K

+0.12%

Jun 30, 2025

The Vanguard Group, Inc.

16.68M

10.47%

+329.29K

+2.01%

Jun 30, 2025

T. Rowe Price Investment Management, Inc.

16.05M

10.07%

-126.81K

-0.78%

Jun 30, 2025

Capital World Investors

12.54M

7.87%

+178.19K

+1.44%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

8.73M

5.47%

-171.64K

-1.93%

Jun 30, 2025

Bellevue Asset Management AG

7.85M

4.93%

--

Jun 30, 2025

Wellington Management Company, LLP

6.35M

3.98%

-2.07M

-24.60%

Jun 30, 2025

Deep Track Capital LP

4.89M

3.07%

+327.34K

+7.17%

Jun 30, 2025

State Street Global Advisors (US)

4.53M

2.84%

-314.74K

-6.50%

Jun 30, 2025

Two Sigma Investments, LP

4.46M

2.8%

+678.11K

+17.95%

Jun 30, 2025

持股ETF



更新時間: 9月6日週六

機構名稱

佔比

iShares Russell 3000 ETF

0%

iShares Russell 1000 Value ETF

0%

Fidelity MSCI Health Care Index ETF

0%

VanEck Morningstar SMID Moat ETF

0%

Fidelity Nasdaq Composite Index ETF

0%

JPMorgan BetaBuilders US Mid Cap Equity ETF

0%

iShares Russell 2500 ETF

0%

iShares US Small-Cap Equity Factor ETF

0%

Schwab U.S. Broad Market ETF

0%

iShares MSCI USA Small-Cap Min Vol Factor ETF

0%

iShares Russell 3000 ETF

佔比0%

iShares Russell 1000 Value ETF

佔比0%

Fidelity MSCI Health Care Index ETF

佔比0%

VanEck Morningstar SMID Moat ETF

佔比0%

Fidelity Nasdaq Composite Index ETF

佔比0%

JPMorgan BetaBuilders US Mid Cap Equity ETF

佔比0%

iShares Russell 2500 ETF

佔比0%

iShares US Small-Cap Equity Factor ETF

佔比0%

Schwab U.S. Broad Market ETF

佔比0%

iShares MSCI USA Small-Cap Min Vol Factor ETF

佔比0%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據